Early Changes in Lymphocyte Counts Predict Clinical Outcomes in Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab
Journal of Gastroenterology and Hepatology · 05.10.2026
DOI: 10.1111/jgh.70793 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 05.10.2026. Verfasst von Yuichi Honma und 35 weiteren Autor:innen. Beteiligte Einrichtung: Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Durvalumab plus tremelimumab (Dur/Tre) has shown promising efficacy in advanced hepatocellular carcinoma (HCC), but predictive biomarkers remain unclear. This study aimed to determine whether early changes in peripheral blood lymphocyte counts during Dur/Tre therapy can predict clinical outcomes.
Methods
In this multicenter retrospective study, we evaluated 299 patients with advanced HCC to assess whether early changes in peripheral blood lymphocyte counts predict clinical outcomes during Dur/Tre therapy. Changes in lymphocyte counts at 2 weeks after treatment initiation (2w‐Δlymphocyte) were analyzed in relation to objective response rate (ORR), progression‐free survival (PFS), and overall survival.
Results
Patients with a high‐2w‐Δlymphocyte (> +107/μL) demonstrated a significantly higher ORR (29.6% vs. 14.0%, p < 0.001) and longer PFS (4.3 vs. 2.8 months, p = 0.035) compared with those with a low‐2w‐Δlymphocyte (≤ +107/μL). Subgroup analyses showed that higher 2w‐Δlymphocyte values were associated with better PFS across modified albumin–bilirubin grades ( p = 0.011), Barcelona Clinic Liver Cancer stages ( p = 0.007), and baseline lymphocyte‐to‐monocyte ratio ( p < 0.001).
Conclusions
Early increases in peripheral blood lymphocyte counts, particularly 2w‐Δlymphocyte, may be associated with treatment response to Dur/Tre and provide complementary dynamic information to established prognostic factors. Although a favorable association with PFS was observed, this association was attenuated after propensity score matching. Further prospective studies are warranted to validate the clinical utility of 2w‐Δlymphocyte.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
- Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
ORCID-Profile: Yuichi Honma, Shigeo Shimose, Takanori Ito, Issei Saeki, Joji Tani, Takanori Matsuura, Tetsu Tomonari, Yasuto Takeuchi, Nobuhito Taniki, Ryu Sasaki, Takeshi Hatanaka, Satoru Kakizaki, Hideki Iwamoto, Tomotake Shirono, Norikazu Tanabe, Takafumi Yamamoto, Atsushi Naganuma, Hisamitsu Miyaaki, Sohji Nishina, Nobuhiro Nakamoto, Motoyuki Otsuka, Tetsuji Takayama, Yuzo Kodama, Hideki Kobara, Taro Takami, Hiroki Kawashima, Takumi Kawaguchi, Masaru Harada
Zitieren
APA
Honma, Y., Shimose, S., Ito, T., Saeki, I., Tani, J., Matsuura, T., Tomonari, T., Takeuchi, Y., Taniki, N., Sasaki, K., Sasaki, R., Hatanaka, T., Kakizaki, S., Yoshioka, N., Naito, T., Takeuchi, M., Yasunaka, T., Sakata, M., Iwamoto, H., …, & Harada, M. (2026). Early Changes in Lymphocyte Counts Predict Clinical Outcomes in Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70793
Vancouver
Honma Y, Shimose S, Ito T, Saeki I, Tani J, Matsuura T, et al. Early Changes in Lymphocyte Counts Predict Clinical Outcomes in Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab. Journal of Gastroenterology and Hepatology. 2026. doi:10.1111/jgh.70793
BibTeX
@article{Honma2026,
author = {Honma, Yuichi and Shimose, Shigeo and Ito, Takanori and Saeki, Issei and Tani, Joji and Matsuura, Takanori and Tomonari, Tetsu and Takeuchi, Yasuto and Taniki, Nobuhito and Sasaki, Kyo and Sasaki, Ryu and Hatanaka, Takeshi and Kakizaki, Satoru and Yoshioka, Naoki and Naito, Takehito and Takeuchi, Mamiko and Yasunaka, Tetsuya and Sakata, Masahiro and Iwamoto, Hideki and Shirono, Tomotake and Itano, Satoshi and Tanabe, Norikazu and Yamamoto, Takafumi and Naganuma, Atsushi and Kanayama, Yuki and Miyaaki, Hisamitsu and Nishina, Sohji and Nakamoto, Nobuhiro and Otsuka, Motoyuki and Takayama, Tetsuji and Kodama, Yuzo and Kobara, Hideki and Takami, Taro and Kawashima, Hiroki and Kawaguchi, Takumi and Harada, Masaru},
title = {Early Changes in Lymphocyte Counts Predict Clinical Outcomes in Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
doi = {10.1111/jgh.70793}
}
EUVIMED